In cells grown under normal conditions, the biosensor showed a perfect movie of metabolic homeostasis: aspartate levels remained high while the cells steadily proliferated. After 48 hours, cell division slowed as the cells grew crowded, and aspartate levels started decreasing as nutrients in the media were expended.
To understand what happens during conditions of aspartate limitation, the authors focused on one of their favorite enzymes: succinate dehydrogenase (SDH). SDH is lost in many cancers and mitochondrial disorders, disrupting key processes involved with cellular energy production. The consequences of SDH loss are many but notably involve both aspartate depletion and succinate build-up.
When the authors chemically inhibited SDH, disrupting aspartate synthesis, they observed an interesting result: aspartate levels first plummeted (as expected), but then they went back up. Despite aspartate rebound, cell proliferation never recovered.
There could be two explanations for the rebound of aspartate in SDH-inhibited cells: 1) the cells may be increasing aspartate acquisition, or 2) there is decreased consumption through the pathways that normally use aspartate.
“We had no idea what was going on for 6 months and were wondering ‘how could we possibly explain this?’” Dr. Sullivan continues. “We did mass spectrometry to make sure it wasn’t an artifact.”
Not only did this mass spectrometry confirm the biosensor observations, it found a surprising impact of this aspartate rebound: in SDH-inhibited cells, there was a striking decrease in pyrimidine levels.
“It was very unclear why there would be this specific deficiency in pyrimidine biosynthesis,” says Dr. Sullivan. “So, we did what all good scientists would do, and we looked through the literature.”
This literature search revealed an unexpected source of insight: an enzyme that’s been studied since the 70s. Enter aspartate transcarbamylase (ATCase), which directly converts aspartate into pyrimidine intermediates. This reaction is the first step in pyrimidine biosynthesis.
“E. coli ATCase has been a workhorse of molecular biology since the 70s and 80s,” explains Dr. Sullivan.
Intriguingly, succinate—which builds up in SDH-inhibited cells—can inhibit the activity of ATCase, at least in E. coli.
“It was lucky for us that people had been studying this particular enzyme for a long time,” adds Sokolov. He was tasked with proving the hypothesis that succinate build-up inhibits human ATCase.
“We needed to go back in time and do some old-fashioned biochemistry,” he says. “And I couldn’t have done this without the help of others at the Hutch. I was going door to door, getting all these random reagents with the goal of expressing human ATCase.”
These collaborations paid off in a big way. The authors showed that indeed succinate can inhibit the ability of human ATCase to consume aspartate.
“The lightbulb moment was when I did the enzyme activity assay, and the wells with added succinate showed a visible decrease in ATCase activity” he continues. "It's still wild to me that you can take an enzyme and feed it substrate, and it knows what to do.”
To confirm this mechanism in cells, they returned to their SDH-inhibited cells and treated with additional inhibitors that reduced succinate concentrations. With lower succinate levels in the cell, ATCase activity was restored, and aspartate levels fell as expected.
To sum up the biochemistry: SDH deficiency initially causes a drop in aspartate levels and a pile up of succinate. The excess succinate inhibits ATCase, and this prevents aspartate conversion to pyrimidines. All this leads to an eventual rebound of aspartate levels.